A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

Trial Profile

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Ademetionine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms HORIZON Study
  • Sponsors MSI Methylation Sciences
  • Most Recent Events

    • 27 Jan 2016 Status changed from active, no longer recruiting to completed, as per MSI Methylation sciences media release.
    • 27 Jan 2016 Results published in MSI Methylation sciences media release.
    • 27 Jan 2016 Primary endpoint has not been met. (Change in the total Hamilton Depression Rating Scale (HAM-D17) between randomization and end of study.), as per MSI Methylation sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top